Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics has secured $5 million from institutional and professional investors to advance its CHM CDH17 CAR-T program through a Phase 1/2 trial. The capital raising, which includes a significant investment from Executive Chairman Paul Hopper, comes with a steep discount on share prices and aims to bolster the company’s clinical trial pipeline, including promising trials in cancer therapy. This strategic move reflects Chimeric’s commitment to leading the cell therapy space with innovative treatments.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.